Analyst Price Target is $7.50
▲ +265.85% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MDxHealth in the last 3 months. The average price target is $7.50, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 265.85% upside from the last price of $2.05.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in MDxHealth. This Buy consensus rating has held steady for over two years.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Read More
